CEO
Accuray Accelerates Transformation Efforts with Appointments of Experienced Executive Leaders
Accuray; transformation; executive appointments; Steve La Neve; CEO; Suzanne Winter; organizational change; operational transformation; med-tech; leadership transition
The 5 Most Powerful Women in Biopharma: 2025 News & Key Figures
powerful women; biopharma; female CEO; Reshma Kewalramani; Yvonne Greenstreet; Sarah Boyce; Emma Walmsley; Belén Garijo; leadership
GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026
GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline
Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the ‘Very Fair’ Deal and Plans to Polish a Rough Diamond
Genmab; Merus; petosemtamab; acquisition; oncology; head and neck cancer; bispecific antibody; FDA Breakthrough Therapy; pipeline expansion; biotech; $8B deal; CEO perspective
GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed
Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning
Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026
Merck KGaA; Kai Beckmann; Belén Garijo; CEO Succession; Electronics Business; Executive Board; Leadership Transition; Healthcare sector; Corporate governance; Strategic transformation
Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026
Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance
Pfizer Veteran Suneet Varma Named CEO of Phase 3-Ready Biotech Startup Intent Biologics
Suneet Varma; Pfizer vet; Intent Biologics; CEO appointment; regenerative medicine; Phase 3 clinical trials; biotech startup; inflammation and immunology
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO
Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership
Novo Nordisk’s Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK
Novo Nordisk; leadership shakeup; new CEO; Maziar Mike Doustdar; share price drop; obesity drug market; competition; GSK; regulatory affairs; Former FDA